MATRIX HCV--a newly developed semiautomated dot-immunoassay.
MATRIX HCV, a newly developed semiautomated assay for the detection of antibodies against individual antigens of the hepatitis C virus, was evaluated on blood donor specimens and compared with the results of another recombinant immuno-blot assay. 399 samples derived from a low-prevalence population revealed an assay specificity of 99.2% for MATRIX HCV. Investigation of 133 samples with repeat reactive screening results showed that the MATRIX HCV assay had a higher ability to discriminate between a clear reactive and nonreactive result compared to the recombinant immuno-blot assay.
Böcher
M
M
Abbott GmbH Diagnostika, Wiesbaden, Germany.
Vockel
A
A
D000956:Antigens, Viral; D001331:Automation; D001782:Blood Donors; D001803:Blood Transfusion / Q000592:standards; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D018937:Hepatitis C Antibodies / Q000097:blood*; D006801:Humans; D007118:Immunoassay / Q000379:methods; D011994:Recombinant Proteins; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000956:Antigens, Viral; D018937:Hepatitis C Antibodies; D011994:Recombinant Proteins